Masimo Announces New Peer-Reviewed Study Finds That Masimo SET Pulse Oximetry Measures Accurately Across The Skin Tone Range Even During Low Perfusion
Portfolio Pulse from Benzinga Newsdesk
Masimo (NASDAQ:MASI) announced results from a peer-reviewed study showing its SET Pulse Oximetry accurately measures oxygen saturation across different skin tones, even under low perfusion. The study, published in the Journal of Clinical Monitoring and Computing, analyzed over 7,000 data samples from 75 subjects, finding no significant difference in accuracy or bias between Black and White subjects. This adds to evidence supporting the reliability of Masimo SET Pulse Oximetry in diverse conditions.
February 08, 2024 | 9:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Masimo's recent study demonstrates the accuracy of its SET Pulse Oximetry across different skin tones and perfusion levels, potentially reinforcing its market position and product trustworthiness.
The study's findings could enhance Masimo's reputation for producing reliable and inclusive medical technology, potentially increasing demand for its products. Given the focus on health equity and the importance of accurate medical devices across diverse populations, this positive news could lead to a short-term uptick in investor confidence and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100